Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 13, 2026, 6:23 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 34 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Ocrelizumab IV Clear all
Terminated Phase 3 Interventional Results available

A Study of Ocrelizumab Compared to Placebo in Patients With Active Rheumatoid Arthritis Who Don't Have a Response to Anti-TNF-α Therapy (SCRIPT)

NCT00476996
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Leflunomide, Methotrexate, Ocrelizumab, Placebo
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years and older
Enrollment
836 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2018
U.S. locations
144
States / cities
Anniston, Alabama • Birmingham, Alabama • Huntsville, Alabama + 116 more
Source: ClinicalTrials.gov public record
Updated Aug 11, 2019 · Synced Sep 13, 2026, 6:23 PM EDT
Completed No phase listed Observational

A Study to Assess New Participant's Perspectives Beyond Clinical Efficacy of Monoclonal Antibody-Based Relapsing Remitting Multiple Sclerosis (RRMS) Treatments

NCT06127095
View directory record Official record
Conditions
Multiple Sclerosis, Relapsing-Remitting
Interventions
Not listed
Lead sponsor
Biogen
Industry
Eligibility
18 Years and older
Enrollment
474 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Cambridge, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 17, 2024 · Synced Sep 13, 2026, 6:23 PM EDT
Completed Phase 1 Interventional

A Study To Investigate The Pharmacokinetics, Safety, And Tolerability Of Subcutaneous Ocrelizumab Administration In Participants With Multiple Sclerosis

NCT03972306
View directory record Official record
Conditions
Multiple Sclerosis (MS)
Interventions
Ocrelizumab, rHuPH20
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years to 65 Years
Enrollment
134 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
18
States / cities
Aurora, Colorado • Washington D.C., District of Columbia • Alexandria, Louisiana + 15 more
Source: ClinicalTrials.gov public record
Updated Jul 7, 2025 · Synced Sep 13, 2026, 6:23 PM EDT
Completed Phase 4 Interventional

Prospective Study to Assess Disease Activity and Biomarkers in Minority Participants With Relapsing Multiple Sclerosis (RMS) After Initiation and During Treatment With Ocrelizumab

NCT04377555
View directory record Official record
Conditions
Multiple Sclerosis, Relapsing
Interventions
Ocrelizumab
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
179 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
26
States / cities
Phoenix, Arizona • Los Angeles, California • Washington D.C., District of Columbia + 19 more
Source: ClinicalTrials.gov public record
Updated Feb 3, 2026 · Synced Sep 13, 2026, 6:23 PM EDT
Active, not recruiting Phase 3 Interventional Results available

A Study to Evaluate the Efficacy and Safety of Ocrelizumab in Adults With Primary Progressive Multiple Sclerosis

NCT04035005
View directory record Official record
Conditions
Multiple Sclerosis, Primary Progressive
Interventions
Ocrelizumab, Placebo
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years to 65 Years
Enrollment
1,013 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2028
U.S. locations
8
States / cities
Washington D.C., District of Columbia • Clearwater, Florida • Orlando, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Feb 22, 2026 · Synced Sep 13, 2026, 6:23 PM EDT
Completed No phase listed Observational

A Systems Approach to Understanding Disease Processes in Multiple Sclerosis

NCT05081700
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
All patients in the study will be treated with ocrelizumab
Drug
Lead sponsor
Providence Health & Services
Other
Eligibility
18 Years to 60 Years
Enrollment
14 participants
Timeline
2020 – 2023
U.S. locations
2
States / cities
Portland, Oregon • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Oct 1, 2024 · Synced Sep 13, 2026, 6:23 PM EDT
Recruiting Phase 1Phase 2 Interventional

Ocrelizumab for Psychosis by Autoimmunity

NCT03971487
View directory record Official record
Conditions
Schizo-Affective Type of Psychosis, Schizophrenia
Interventions
Psychosis and cognitive assessments, Physical and neuro-cognitive evaluations, Safety labs and electrocardiogram, Ocrelizumab infusion
Behavioral · Diagnostic Test · Biological
Lead sponsor
The Methodist Hospital Research Institute
Other
Eligibility
18 Years to 35 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2028
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 31, 2026 · Synced Sep 13, 2026, 6:23 PM EDT
Active, not recruiting Not applicable Interventional

Traditional Versus Early Aggressive Therapy for Multiple Sclerosis Trial

NCT03500328
View directory record Official record
Conditions
Multiple Sclerosis, Relapsing-Remitting
Interventions
Natalizumab/natalizumab-sztn, Alemtuzumab, Ocrelizumab, Rituximab/rituximab-arrx/rituximab-abbs/rituximab-pvvr, Cladribine, Ofatumumab, Ublituximab-xiiy, Ocrelizumab and hyaluronidase-ocsq, Glatiramer acetate, Interferons (intramuscular, subcutaneous, pegylated) Teriflunomide, Fumarates (dimethyl, diroximel, monomethyl) Fingolimod, Siponimod, Ozanimod, Ponesimod
Other
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 60 Years
Enrollment
900 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
47
States / cities
Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 38 more
Source: ClinicalTrials.gov public record
Updated Sep 1, 2026 · Synced Sep 13, 2026, 6:23 PM EDT
Recruiting Phase 4 Interventional

Study of Ublituximab for Ocrelizumab Wearing-Off in Multiple Sclerosis

NCT07389590
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Ublituximab, Ocrelizumab
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 65 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated May 5, 2026 · Synced Sep 13, 2026, 6:23 PM EDT
Terminated Phase 2 Interventional Results available

A Study to Evaluate Ocrelizumab in Combination With Methotrexate Compared With Infliximab Plus Methotrexate in Patients With Active Rheumatoid Arthritis Currently Responding Inadequately to Etanercept or Adalimumab

NCT00808210
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Infliximab, Methotrexate, Methylprednisolone, Ocrelizumab, Placebo
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
53
States / cities
Birmingham, Alabama • Jonesboro, Arkansas • Murrieta, California + 49 more
Source: ClinicalTrials.gov public record
Updated Nov 5, 2020 · Synced Sep 13, 2026, 6:23 PM EDT
Completed No phase listed Observational

Time and Motion Study for Ocrelizumab and Ofatumumab Administration in Relapsing Multiple Sclerosis

NCT04676555
View directory record Official record
Conditions
Relapsing Forms of Multiple Sclerosis
Interventions
Ocrelizumab, Ofatumumab
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 100 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
1
States / cities
Lutherville, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 23, 2022 · Synced Sep 13, 2026, 6:23 PM EDT
Completed Phase 3 Interventional Results available

Study to Explore the Mechanism of Action of Ocrelizumab and B-Cell Biology in Participants With Relapsing Multiple Sclerosis (RMS) or Primary Progressive Multiple Sclerosis (PPMS)

NCT02688985
View directory record Official record
Conditions
Relapsing Multiple Sclerorsis, Multiple Sclerosis, Primary Progressive
Interventions
Ocrelizumab, Lumbar Puncture, Methyloprednisolone, Antihistamine
Drug · Procedure
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
131 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2023
U.S. locations
12
States / cities
Palo Alto, California • San Francisco, California • Aurora, Colorado + 9 more
Source: ClinicalTrials.gov public record
Updated Jun 3, 2024 · Synced Sep 13, 2026, 6:23 PM EDT
Terminated Phase 3 Interventional Results available

Study to Evaluate the Effectiveness and Safety of Ocrelizumab in Participants With Early Stage Relapsing Remitting Multiple Sclerosis (RRMS)

NCT03085810
View directory record Official record
Conditions
Multiple Sclerosis, Relapsing-Remitting
Interventions
Ocrelizumab
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years to 55 Years
Enrollment
1,225 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
26
States / cities
Irvine, California • Sunnyvale, California • Aurora, Colorado + 23 more
Source: ClinicalTrials.gov public record
Updated Jan 14, 2025 · Synced Sep 13, 2026, 6:23 PM EDT
Active, not recruiting Phase 3 Interventional

A Study to Evaluate the Efficacy and Safety of Fenebrutinib Compared With Ocrelizumab in Adult Participants With Primary Progressive Multiple Sclerosis

NCT04544449
View directory record Official record
Conditions
Multiple Sclerosis, Primary Progressive
Interventions
Fenebrutinib, Ocrelizumab, Placebo matched to ocrelizumab, Placebo matched to fenebrutinib
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years to 65 Years
Enrollment
985 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
43
States / cities
Homewood, Alabama • Berkeley, California • Fullerton, California + 40 more
Source: ClinicalTrials.gov public record
Updated Sep 2, 2026 · Synced Sep 13, 2026, 6:23 PM EDT
Active, not recruiting Phase 4 Interventional

Ocrelizumab Discontinuation in Relapsing Multiple Sclerosis

NCT05285891
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Ocrelizumab, Placebo for Ocrelizumab
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 55 Years
Enrollment
123 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2032
U.S. locations
13
States / cities
New Haven, Connecticut • Washington D.C., District of Columbia • Chicago, Illinois + 10 more
Source: ClinicalTrials.gov public record
Updated Aug 31, 2026 · Synced Sep 13, 2026, 6:23 PM EDT
Completed Phase 3 Interventional Results available

A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Participants With Relapsing Multiple Sclerosis

NCT01412333
View directory record Official record
Conditions
Relapsing Multiple Sclerosis
Interventions
Interferon beta-1a, Ocrelizumab-matching placebo, Ocrelizumab, Interferon beta-1a-matching placebo
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years to 55 Years
Enrollment
835 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2022
U.S. locations
48
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Tucson, Arizona + 43 more
Source: ClinicalTrials.gov public record
Updated Mar 7, 2024 · Synced Sep 13, 2026, 6:23 PM EDT
Completed Phase 2 Interventional Results available

A Study of the Efficacy and Safety of Ocrelizumab in Patients With Relapsing-Remitting Multiple Sclerosis

NCT00676715
View directory record Official record
Conditions
Multiple Sclerosis, Relapsing-Remitting
Interventions
Placebo, Ocrelizumab, Avonex
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
220 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2023
U.S. locations
26
States / cities
Phoenix, Arizona • Berkeley, California • San Francisco, California + 22 more
Source: ClinicalTrials.gov public record
Updated Dec 30, 2024 · Synced Sep 13, 2026, 6:23 PM EDT
Active, not recruiting Phase 3 Interventional Results available

A Study to Evaluate the Efficacy, Safety and Pharmacokinetics (PK) of a Higher Dose of Ocrelizumab in Adults With Relapsing Multiple Sclerosis (RMS)

NCT04544436
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Ocrelizumab, Antihistamine, Methylprednisolone
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years to 55 Years
Enrollment
864 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2028
U.S. locations
25
States / cities
Cullman, Alabama • Homewood, Alabama • Phoenix, Arizona + 22 more
Source: ClinicalTrials.gov public record
Updated Jul 29, 2026 · Synced Sep 13, 2026, 6:23 PM EDT
Completed Phase 2 Interventional Results available

Phase 2 Study IV QUZYTTIR™ (Cetirizine Hydrochloride Injection) vs V Diphenhydramine

NCT04189588
View directory record Official record
Conditions
Oncology Patients Receiving Chemotherapy
Interventions
Cetirizine HCl 10 mg/mL, Diphenhydramine 50 mg/mL, anti-CD20 such as Rituximab or Paclitaxel
Drug
Lead sponsor
TerSera Therapeutics LLC
Industry
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
7
States / cities
Napa, California • Rancho Mirage, California • Santa Rosa, California + 4 more
Source: ClinicalTrials.gov public record
Updated Oct 5, 2023 · Synced Sep 13, 2026, 6:23 PM EDT
Terminated Phase 3 Interventional Results available

A Study of Ocrelizumab Compared to Placebo in Patients With Active Rheumatoid Arthritis Continuing Methotrexate Treatment (STAGE)

NCT00406419
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Methotrexate, ocrelizumab, Placebo
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years and older
Enrollment
1,015 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2015
U.S. locations
1
States / cities
South San Francisco, California
Source: ClinicalTrials.gov public record
Updated Nov 26, 2020 · Synced Sep 13, 2026, 6:23 PM EDT
Completed No phase listed Observational Accepts healthy volunteers Results available

Mechanism of Action of Ocrelizumab in Multiple Sclerosis

NCT03344094
View directory record Official record
Conditions
Multiple Sclerosis, Immune System Diseases
Interventions
ocrelizumab
Drug
Lead sponsor
University of Chicago
Other
Eligibility
18 Years to 65 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Feb 20, 2025 · Synced Sep 13, 2026, 6:23 PM EDT
Completed Phase 3 Interventional Results available

A Study of Ocrelizumab in Participants With Primary Progressive Multiple Sclerosis

NCT01194570
View directory record Official record
Conditions
Multiple Sclerosis, Primary Progressive
Interventions
Ocrelizumab, Placebo
Drug · Other
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years to 55 Years
Enrollment
735 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2022
U.S. locations
37
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Phoenix, Arkansas + 31 more
Source: ClinicalTrials.gov public record
Updated Jan 9, 2024 · Synced Sep 13, 2026, 6:23 PM EDT
Active, not recruiting Phase 4 Interventional

Impact of Ocrelizumab on Cerebrospinal Fluid Biomarkers at Multiple Sclerosis Onset

NCT04466150
View directory record Official record
Conditions
Relapsing Multiple Sclerosis, Clinically Isolated Syndrome
Interventions
Ocrelizumab
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 50 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jan 25, 2026 · Synced Sep 13, 2026, 6:23 PM EDT
Completed Phase 3 Interventional Results available

A Study of Ocrelizumab in Participants With Relapsing Remitting Multiple Sclerosis (RRMS) Who Have Had a Suboptimal Response to an Adequate Course of Disease-Modifying Treatment (DMT)

NCT02637856
View directory record Official record
Conditions
Multiple Sclerosis, Relapsing-Remitting
Interventions
Ocrelizumab
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
608 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
67
States / cities
Cullman, Alabama • Phoenix, Arizona • Tucson, Arizona + 59 more
Source: ClinicalTrials.gov public record
Updated May 25, 2020 · Synced Sep 13, 2026, 6:23 PM EDT